[LH-CG receptor protein expression in epithelial ovarian cancer].
OBJECTIVE
To evaluate the relationship between (LH-CG) receptor expression and prognosis in epithelial ovarian cancer.


METHODS
The relative quantity of LH-CG receptor protein of epithelial ovarian cancer tissuse was detected with semiquantitative western immunobloting in 40 cases. The LH-CG receptor protein was located with immunohistochemistry. The LH-CG receptor was termed high expression if its concentration was more than and/or equal to the median, and low expression if its concentration was less than the median. 36 of the 40 cases were followed up at various intervals, the longest follow up period was 56 months. There were 16 cases with high LH-CG expression and 20 cases with low LH-CG receptor expression in which 9 cases died.


RESULTS
The positive rate of LH-CG receptor protein expression was 72.5% (29/40). The level of LH-CG receptor protein expression in patients with stages I and II was higher than that in patients with stages III and IV, but it is not significant (P > 0.05). The LH-CG receptor concentration in the well-differentiated cancer group was twice as much as that in the poorly-differentiated cancer group. The difference between the well-differentiated group and the poorly-differentiated group was significant (P < 0.05). The 1-year and 3-year survival rates were 83.94% and 67.15% respectively in the high LH-CG receptor expression group. Both of the 1-year and 3-year survival rates were 33. 34% in the low LH-CG receptor expression group. The survival rates of the high expression group was significantly higher than those of the low expression group (P < 0.05). LH-CG receptor expression did not correlate with age, lymph node metastases, the size of residual tumor and CA125.


CONCLUSIONS
The prognosis of patients with high LH-CG receptor expression is better than that of those with low expression.
Second Affiliated Hospital, Henan Medical University, Zhengzhou.
J
J
Cui
Y
Y
Guo
Z
Z
You
D000328:Adult; D000368:Aged; D018394:CA-125 Antigen / Q000378:metabolism; D002277:Carcinoma / Q000378:metabolism*; D018269:Carcinoma, Endometrioid / Q000378:metabolism; D018284:Cystadenocarcinoma, Serous / Q000378:metabolism; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000378:metabolism*; D011974:Receptors, LH / Q000096:biosynthesis*
D018394:CA-125 Antigen; D011974:Receptors, LH